What to Watch in the Day Ahead - Friday, April 24

Drugmaker Biogen Inc is expected to report a higher first-quarter profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera, which has seen burgeoning sales since its launch in 2013. Biogen, which leads the U.S. multiple sclerosis market with five drugs for the condition, recently reported promising data for its Alzheimer's disease drug. Investors will also be looking for commentary on Tecfidera's growth expectations and potential for competition as well as the lo